Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA)

Journal of Neuroscience

Volumn 31, Issue 47, 2011, Pages 16928-16940

  di Cara, Benjamin ^a   Maggio, Roberto ^b   Aloisi, Gabriella ^b   Rivet, Jean Michel ^a   Lundius, Ebba Gregorsson ^c   Yoshitake, Takashi ^c   Svenningsson, Per ^c   Brocco, Mauricette ^a   Gobert, Alain ^a   de Groote, Lotte ^a   Cistarelli, Laetitia ^a   Veiga, Sylvie ^a   de Montrion, Catherine ^a   Rodriguez, Marianne ^a   Galizzi, Jean Pierre ^a   Lockhart, Brian P ^a   Cogé, Francis ^a   Boutin, Jean A ^a   Vayer, Philippe ^a   Verdouw, P Monika ^d   Groenink, Lucianne ^d   Millan, Mark J ^a   more..

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 PHENYL 3 IODOTYRAMINE; ADENYLATE CYCLASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; CHLORAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; HALOPERIDOL; MEMBRANE RECEPTOR; NORADRENALIN; SEROTONIN; THYROXINE DERIVATIVE; TRACE AMINE 1 RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ENZYME PHOSPHORYLATION; FACILITATION; FEMALE; FRONTAL CORTEX; GENE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERTHERMIA; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SUBSTANTIA NIGRA; THERMOREGULATION; TRACE AMINE 1 RECEPTOR GENE; VENTRAL TEGMENTUM;

ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE DELETION; HELA CELLS; HUMANS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RANDOM ALLOCATION; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN;

EID: 81855180541     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2502-11.2011     Document Type: Article

References (72)

1. Ball KT, Budreau D, Rebec GV (2003) Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res 994:203-215.
2. Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, Violin JD, Lefkowitz RJ, Caron MG, Gainetdinov RR (2008) Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 74:585-594.
3. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy"). Neuropsychopharmacology 30:550-560.
4. Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
5. Baumann MH, Clark RD, Rothman RB (2008) Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90:208-217.
6. Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 207:73-83.
7. Berry MD (2004) Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 90:257-271.
8. Bexis S, Docherty JR (2008) Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol 153:591-597.
9. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C (2001) Trace amines: identification of a family of mammalian-coupled receptors. Proc Natl Acad Sci U S A 98:8966-8971.
10. Bradaia A, Trube G, Stalder H, Norcross RD, Ozmen L, Wettstein JG, Pinard A, Buchy D, Gassmann M, Hoener MC, Bettler B (2009) The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A 106:20081-20086.
11. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258.
12. Branchek TA, Blackburn TP (2003) Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol 3:90-97.
13. Bratincsák A, Kovács ZI, Palkovits M (2008) Direct neuronal projection from a brainstem thermosensitive cell group to the preoptic thermoregulatory center. Neuroscience 156:966-972.
14. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188.
15. Burchett SA, Hicks TP (2006) The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 79:223-246.
16. Colado MI, O'Shea E, Green AR (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173:249-263.
17. Docherty JR, Green AR (2010) The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 160:1029-1044.
18. Doyle KP, Suchland KL, Ciesielski TM, Lessov NS, Grandy DK, Scanlan TS, Stenzel-Poore MP (2007) Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury. Stroke 38:2569-2576.
19. Dupré DJ, Baragli A, Rebois RV, Ethier N, Hébert TE (2007) Signalling complexes associated with adenylyl cyclase II are assembled during their biosynthesis. Cell Signal 19:481-489.
20. Feduccia AA, Kongovi N, Duvauchelle CL (2010) Heat increases MDMAenhanced NAcc 5-HT and body temperature, but not MDMA selfadministration. Eur Neuropsychopharmacol 20:884-894.
21. Geracitano R, Federici M, Prisco S, Bernardi G, Mercuri NB (2004) Inhibitory effects of trace amines on rat midbrain dopaminergic neurons. Neuropharmacology 46:807-814.
22. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221.
23. Gobert A, Billiras R, Cistarelli L, Millan MJ (2004) Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J Neurosci Methods 140:141-152.
24. Gobert A, Brocco M, Dekeyne A, Di Cara B, Bouchez G, Lejeune F, Gannon RL, Millan MJ (2009) Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology 34:1039-1056.
25. Gough B, Imam SZ, Blough B, Slikker W Jr, Ali SF (2002) Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann N Y Acad Sci 965:410-420.
26. Grandy DK (2007) Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 116:355-390.
27. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
28. Guiard BP, Guilloux JP, Reperant C, Hunt SP, Toth M, Gardier AM (2007) Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 72:1411-1418.
29. Hargreaves GA, Hunt GE, Cornish JL, McGregor IS (2007) High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")-induced Fos expression in a region-specific manner. Neuroscience 145:764-774.
30. Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK, Scanlan TS (2006) Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J Med Chem 49:1101-1112.
31. Hauber W (2010) Dopamine release in the prefrontal cortex and striatum: temporal and behavioural aspects. Pharmacopsychiatry 43 [Suppl 1]:S32-S41.
32. Haycock JW (1993) Multiple signaling pathways in bovine chromaffin cells regulate tyrosine hydroxylase phosphorylation at Ser19, Ser31, and Ser40. Neurochem Res 18:15-26.
33. Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266:5650-5657.
34. Haycock JW, Lew JY, Garcia-Espana A, Lee KY, Harada K, Meller E, Goldstein M (1998) Role of serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site-and phosphospecific antibodies and sitedirected mutagenesis. J Neurochem 71:1670-1675.
35. Herin DV, Liu S, Ullrich T, Rice KC, Cunningham KA (2005) Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) 178:505-513.
36. Hu LA, Zhou T, Ahn J, Wang S, Zhou J, Hu Y, Liu Q (2009) Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. Biochem J 424:39-45.
37. Iravani MM, Asari D, Patel J, Wieczorek WJ, Kruk ZL (2000) Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 36:275-285.
38. Jaworski JN, Kozel MA, Philpot KB, Kuhar MJ (2003) Intra-accumbal injection of CART (cocaine-amphetamine regulated transcript) peptide reduces cocaine-induced locomotor activity. J Pharmacol Exp Ther 307:1038-1044.
39. Johansen PØ, Krebs TS (2009) How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol (Oxford) 23:389-391.
40. Karlsen SN, Spigset O, Slørdal L (2008) The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic Clin Pharmacol Toxicol 102:15-24.
41. Ledonne A, Federici M, Giustizieri M, Pessia M, Imbrici P, Millan MJ, Bernardi G, Mercuri NB (2010) Trace amines depress D(2)-autoreceptormediated responses on midbrain dopaminergic cells. Br J Pharmacol 160:1509-1520.
42. Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238.
43. Lew JY, Garcia-Espana A, Lee KY, Carr KD, Goldstein M, Haycock JW, Meller E (1999) Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity. Mol Pharmacol 55:202-209.
44. Liberles SD, Buck LB (2006) A second class of chemosensory receptors in the olfactory epithelium. Nature 442:645-650.
45. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521.
46. Lindemann L, Hoener MC (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26:274-281.
47. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, Bettler B, Wettstein JG, Borroni E, Moreau JL, Hoener MC (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324:948-956.
48. Lindgren N, Xu ZQ, Herrera-Marschitz M, Haycock J, Hökfelt T, Fisone G (2001) Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 13:773-780.
49. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
50. Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP (2009) International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol Rev 61:1-8.
51. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358-368.
52. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") to rats. Br J Pharmacol 135:170-180.
53. Millan MJ, Audinot V, Rivet JM, Gobert A, Vian J, Prost JF, Spedding M, Peglion JL (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol 260:3-5.
54. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A (2000a) Agonist and antagonist actions of yohimbine as compared with fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35:79-95.
55. Millan MJ, Lejeune F, Gobert A (2000b) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138.
56. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C (2008) Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 29:454-464.
57. Mlinar B, Corradetti R (2003) Endogenous 5-HT, released by MDMA through serotonin transporter-and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur J Neurosci 18:1559-1571.
58. Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, Scanlan TS, Miller GM (2010) Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice. J Neurosci Res 88:1962-1969.
59. Ramamoorthy S, Samuvel DJ, Buck ER, Rudnick G, Jayanthi LD (2007) Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP. J Biol Chem 282:11639-11647.
60. Rodsiri R, Spicer C, Green AR, Marsden CA, Fone KCF (2011) Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology (Berl) 213:365-376.
61. Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89:1817-1821.
62. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10:638-642.
63. Schifano F (2004) A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 173:242-248.
64. Sotnikova TD, Zorina OI, Ghisi V, Caron MG, Gainetdinov RR (2008) Trace amine associated receptor 1 and movement control. Parkinsonism Relat Disord 14 [Suppl 2]:S99-S102.
65. Stalder H, Hoener MC, Norcross RD (2011) Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773). Bioorg Med Chem Lett 21:1227-1231.
66. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311:77-80.
67. Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999) Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology (Berl) 143:365-372.
68. Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M (2002) Acute psychological and neurophysiological effects ofMDMAin humans. J Psychoactive Drugs 34:171-184.
69. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, Branchek T, Gerald CP (2007) The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6:628-639.
70. Xie Z, Miller GM (2007) Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 321:128-136.
71. Xie Z, Miller GM (2008) Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. J Pharmacol Exp Ther 325:617-628.
72. Xie Z, Westmoreland SV, Miller GM (2008) Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J Pharmacol Exp Ther 325:629-640.